Simcere Pharmaceutical Group Limited (HKG:2096)

HKG:2096 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,072	3,512	1,953	2,007	1,658	973.14
Short-Term Investments	955.31	65.53	10	11.14	964.23	1,210
Cash & Short-Term Investments	4,027	3,578	1,963	2,018	2,623	2,183
Cash Growth	50.49%	82.29%	-2.76%	-23.04%	20.12%	-33.31%
Accounts Receivable	2,407	2,858	2,704	2,645	2,339	2,399
Other Receivables	19	100.55	60.06	50.73	39.89	37.37
Receivables	2,527	3,059	2,764	2,695	2,379	2,436
Inventory	632.91	673.85	684.09	770.14	371.59	290.96
Other Current Assets	279.68	79.63	81.02	155.13	85.61	69.24
Total Current Assets	7,467	7,390	5,492	5,639	5,458	4,980
Property, Plant & Equipment	2,739	2,532	2,327	2,170	2,139	1,931
Long-Term Investments	2,817	2,352	1,893	1,580	2,258	2,651
Goodwill	142.47	142.47	142.47	142.47	172.79	172.79
Other Intangible Assets	1,481	1,443	1,025	715.79	379.9	59.69
Long-Term Deferred Tax Assets	603.48	520.71	435.59	317	326.71	289.97
Other Long-Term Assets	211.86	346.03	183.83	188.95	53.79	76.56
Total Assets	15,461	14,726	11,600	10,854	10,789	10,161

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	239.15	249.03	276.06	317.22	335.43	323.95
Accrued Expenses	1,082	999.22	1,032	1,045	1,124	1,032
Short-Term Debt	1,050	1,052	1,050	762.43	1,184	991.57
Current Portion of Long-Term Debt	0.68	0.7	0.72	252.71	108.37	538.51
Current Portion of Leases	56.23	57.34	67.56	79.85	58.76	31.56
Current Income Taxes Payable	88.42	65.7	154.36	17.9	10.56	16.16
Current Unearned Revenue	676.31	687.06	28.16	43.31	63.34	26.14
Other Current Liabilities	733.08	234.22	119.76	167	82.41	103.7
Total Current Liabilities	3,926	3,345	2,729	2,686	2,967	3,064
Long-Term Debt	6.93	7.48	8.25	205.85	-	-
Long-Term Leases	58.15	69.64	82.42	128.4	155.92	74.24
Long-Term Unearned Revenue	513.71	472.53	400.15	393.11	403.35	417.61
Long-Term Deferred Tax Liabilities	80.31	68.04	72.7	102.68	115.29	142.77
Other Long-Term Liabilities	1,389	1,348	1,174	115	-	-
Total Liabilities	5,974	5,311	4,466	3,631	3,641	3,698

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	4,627	4,619	3,174	3,174	3,081	3,003
Retained Earnings	-	4,326	3,447	3,837	3,831	3,294
Comprehensive Income & Other	4,797	463.61	513.29	211.61	219.72	139.96
Total Common Equity	9,424	9,408	7,134	7,223	7,132	6,437
Minority Interest	63.31	6.72	-	-	16.06	25.76
Shareholders' Equity	9,488	9,415	7,134	7,223	7,148	6,463
Total Liabilities & Equity	15,461	14,726	11,600	10,854	10,789	10,161

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,172	1,187	1,209	1,429	1,507	1,636
Net Cash (Debt)	2,855	2,391	753.22	589.08	1,116	547.34
Net Cash Growth	97.36%	217.40%	27.86%	-47.21%	103.86%	-
Net Cash Per Share	1.12	0.96	0.30	0.23	0.43	0.21
Filing Date Shares Outstanding	2,552	2,596	2,486	2,617	2,660	2,628
Total Common Shares Outstanding	2,552	2,596	2,486	2,617	2,660	2,628
Working Capital	3,541	4,045	2,764	2,953	2,492	1,916
Book Value Per Share	3.69	3.62	2.87	2.76	2.68	2.45
Tangible Book Value	7,801	7,823	5,966	6,364	6,579	6,205
Tangible Book Value Per Share	3.06	3.01	2.40	2.43	2.47	2.36
Machinery	-	2,981	2,962	2,632	2,811	2,528
Construction In Progress	-	756.39	400.43	343.47	202.13	95.75

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 31, 2026

Data Sources Report a data error